Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists
-
By
-
Zayed Rashid
-
Selamawit Woldesenbet
-
Mujtaba Khalil
-
Abdullah Altaf
-
Shahzaib Zindani
-
Areesh Mevawalla
-
Azza Sarfraz
-
Khalid Mumtaz
-
Timothy M. Pawlik
-
February 26, 2026
-
Clinical Scorecard: Cancer Rates in Patients Treated with Glucagon-Like Peptide-1 Receptor Agonists
At a Glance
| Category | Detail |
|---|
| Condition | Cancer incidence in patients treated with GLP-1 receptor agonists |
| Key Mechanisms | GLP-1 RAs mimic incretins, influencing insulin and glucagon secretion, and altering pathways involved in tumorigenesis. |
| Target Population | Adults aged 18-64 with type 2 diabetes mellitus (T2DM) |
| Care Setting | Outpatient and inpatient settings using a national insurance database |
Key Highlights
- GLP-1 RAs may lower colorectal cancer incidence in diabetes patients.
- Potential increased risk of thyroid cancer linked to GLP-1 RA therapy.
- Conflicting evidence regarding GLP-1 RAs and pancreatic cancer risk.
- Study utilized a large population from the IBM-MarketScan database.
- Focus on common thoracic, gastrointestinal, gynecological, and endocrine cancers.
Guideline-Based Recommendations
Diagnosis
- Utilize validated ICD codes for identifying T2DM and cancer diagnoses.
Management
- Consider GLP-1 RAs for managing diabetes and obesity while monitoring cancer risk.
Monitoring & Follow-up
- Follow patients for cancer incidence post GLP-1 RA initiation.
Risks
- Assess individual patient risk factors for thyroid and pancreatic cancer.
Patient & Prescribing Data
Individuals aged 18-64 diagnosed with T2DM.
GLP-1 RAs are associated with metabolic benefits but require careful monitoring for potential cancer risks.
Clinical Best Practices
- Ensure continuous enrollment in insurance plans for accurate data tracking.
- Exclude patients with prior GLP-1 RA use or cancer diagnosis within specified timeframes.
References
